NCT01844778 - Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Cystic Fibrosis

Interventions

DRUG

Tobramycin Inhalation Powder

Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).

DRUG

Tobramycin inhalation solution

Tobramycin inhalation solution was administered via nebuliser

DRUG

Colistimethate

Colistimethate was administered via nebuliser.

Trial Locations (21)

4031

Novartis Investigative Site, Basel

8032

Novartis Investigative Site, Zurich

9007

Novartis Investigative Site, Sankt Gallen

13353

Novartis Investigative Site, Berlin

28046

Novartis Investigative Site, Madrid

41013

Novartis Investigative Site, Seville

45147

Novartis Investigative Site, Essen

46026

Novartis Investigative Site, Valencia

72076

Novartis Investigative Site, Tübingen

81241

Novartis Investigative Site, München

Unknown

Novartis Investigative Site, Galway

07120

Novartis Investigative Site, Palma de Mallorca

08035

Novartis Investigative Site, Barcelona

SO16 6YD

Novartis Investigative Site, Southampton

CF64 2XX

Novartis Investigative Site, Penarth

b9 5ss

Novartis Investigative Site, Birmingham

BS1 3NU

Novartis Investigative Site, Bristol

HU16 5JQ

Novartis Investigative Site, East Yorkshire

EX2 5DW

Novartis Investigative Site, Exeter

L14 3PE

Novartis Investigative Site, Liverpool

NE1 4LP

Novartis Investigative Site, Newcastle upon Tyne